School of Politics and Global Studies, Consortium for Science, Policy and Outcomes, Center for Nanotechnology in Society, Arizona State University, Tempe, AZ, USA.
Expert Rev Mol Diagn. 2012 Nov;12(8):857-70. doi: 10.1586/erm.12.125.
Theranostics signals the integrated application of molecular diagnostics, therapeutic treatment and patient response monitoring. Such integration has hitherto neglected another crucial dimension: coproduction of theranostic scientific knowledge, novel technological development and broader sociopolitical systems whose boundaries are highly porous. Nanodiagnostics applications to theranostics are one of the most contested and potentially volatile postgenomics innovation trajectories as they build on past and current tensions and promises surrounding both nanotechnology and personalized medicine. Recent science policy research suggests that beneficial outcomes of innovations do not simply flow from the generation of scientific knowledge and technological capability in a linear or automatic fashion. Thus, attempts to offset public concerns about controversial emerging technologies by expert risk assurances can be unproductive. Anticipation provides a more robust basis for governance that supports genuine healthcare progress. This article presents a synthesis of novel policy approaches that directly inform theranostics medicine and the future(s) of postgenomics healthcare.
治疗诊断学标志着分子诊断、治疗处理和患者反应监测的综合应用。这种综合应用迄今为止忽略了另一个关键维度：治疗诊断学科学知识、新的技术发展以及边界高度多孔的更广泛的社会政治系统的共同产生。纳米诊断学在治疗诊断学中的应用是最具争议性和潜在易变性的后基因组创新轨迹之一，因为它们建立在过去和当前围绕纳米技术和个性化医学的紧张局势和承诺之上。最近的科学政策研究表明，创新的有益成果不会简单地从线性或自动的方式从科学知识和技术能力的产生中产生。因此，试图通过专家风险保证来消除公众对有争议的新兴技术的担忧可能是无益的。预期为支持真正的医疗保健进展的治理提供了更强大的基础。本文提出了直接为治疗诊断学医学和后基因组医疗保健的未来提供信息的新颖政策方法的综合。
